Valerio Therapeutics · EURONEXT:ALVIO

Valerio Therapeutics — Investor Presentation (July 2026)

18 slides from Valerio Therapeutics's investor presentation, July 2026

Slide 1: Valerio Therapeutics: The Precision Delivery Of Oligonucleotides Beyond The Liver
Valerio Therapeutics: The Precision Delivery Of Oligonucleotides Beyond The Liver Valerio Therapeutics: The Precision Delivery Of Oligonucleotides Beyond The Liver No n-con fid en tia l Co rpo rat e Presenta tion © Valerio Therapeutics | Euronext Growth Paris: ALVIO — All rights reserved July 2026
Slide 2: Forward-looking statements
ValerioTherapeutics ValerioTherapeutics Forward-looking statements This p resen ta tio n con ta in s cert ai n f or wa r d-lo okin g s ta te m en ts co nce rn in g Valerio Th erap eu tics a n d its acti vities. These f o rw a rd - lo okin g s ta te m en ts are b a s ed o n a ssu mpti o ns t ha t Val
Slide 3: Executive summary: aims to be the next global leader in precision RNA therapeutics
ValerioTherapeutics Executive su mma ry ValerioTherapeutics Valerio Therapeutics ai ms to be the next global leader in precision RNA therapeutics Su mm ary Technology & Pipeline Early-st age bi otech co mp a ny lev eraging a proprieta ry sdAb pl at form to Externally va lid ated tec hnol ogy pl at f
Slide 4: Technology enables LNPs to go from liver-limited to multi-organ tissue targeting
ValerioTherapeutics Executive su mma ry ValerioTherapeutics Valerio’s technology enables LNPs to go from liver-limited to m ult i- organ tissue targeting The P rob l em Lipids a nd LNPs na turally a cc um ul ate in the liver Today's LNP delivery primarily reaches the liver. Every other organ remains
Slide 5: Combines decades of RNA therapeutics development experience with proven leadership
ValerioTherapeutics Executive su mma ry ValerioTherapeutics Valerio Therapeutics co mb ine s de cade s of RNA therapeutics development experience with proven leadership A ma n a g e me n t t e a m with d e ep b io te ch o pe ra tin g experience, b a cke d b y a b o a rd with g lo ba l re a ch acro s
Slide 7: Proprietary platform allows significant time saving to generate optimal and customized V-Bodies
ValerioTherapeutics Te ch nol og y p la tf or m ValerioTherapeutics The proprietary pl atfo rm allows significant ti me saving to generate optimal and customized V - Bodies 1 2 3 2 Fully synthetic hum anized VHH or Proprietary scaffolds with ran do m CDRs Rationale design of CDR regions to crea te b
Slide 8: The V-Body platform addresses the limitations of sdAbs through unique attributes
ValerioTherapeutics Te ch nol og y p la tf or m ValerioTherapeutics The V - Body pl atfo rm addresses the limitations of sdAbs through unique and key attributes Single domain antibodies V - bodies (sdAb) IgG Fab scFv Peptide ~ 15 kDa Camelid- (mAb) V - Bodies sdAb Conventional Small Size, Tissue Pen
Slide 9: Unparalleled in vitro selection process allowing for tailor-made functional binders
ValerioTherapeutics Te ch nol og y p la tf or m ValerioTherapeutics Unparalleled in vitro selection process allowing for tailor-m ad e functional binders V - Select Targe t X 1 Target selection Panning 2 Swift selection through ph ag e display A fully in vitro process for selecting hundreds of hits
Slide 10: Integrated platform allows lead candidate selection in 3 months and development candidate in under 9 months
ValerioTherapeutics Te ch nol og y p la tf or m ValerioTherapeutics Valerio’s integ ra te d pl atfo rm allows lead candidate selection in 3 months and development candidate nomination in less than 9 months Months 2 4 6 8 10 12 14 16 18 20 22 24 Semi Synthetic (Ably nx) 14 to 24 mont hs I m m u n e -
Slide 11: Valerio Etherna: creating next-generation RNA therapeutics
Valerio Therapeutics Valerio Therapeutics Valerio a n d Etherna: creating next-generation RNA therapeutics © Valerio Therapeutics — All rights reserved
Slide 12: Combination of Valerio Therapeutics and Etherna will create a global leader in targeted RNA medicines
ValerioTherapeutics Valerio a n d Etherna ValerioTherapeutics The c om b in ati on of Valerio Therapeutics a n d Etherna will create a global leader in targeted RNA medicines 1 Investor proposition 2 Ha r d-t o - replic ate therap eutics pla tform 3 M iles ton e-driven va lue inflection • Invest in
Slide 13: Combined technologies create a fully integrated platform for targeted RNA therapeutics
ValerioTherapeutics Valerio a n d Etherna ValerioTherapeutics Valerio’s a n d Etherna’s technologies c o m bi n ed will create a fully integrated technology platform for targeted RNA therapeutics Ce ll-targe ting V - Body Ce ll-targe ting LNPs • Differentiated proprietary platf orm of fully synthet
Slide 14: Pipeline designed to rapidly reach value inflection points within each program
ValerioTherapeutics Valerio a n d Etherna ValerioTherapeutics Valerio’s pipeline is designed to rapidly reach value inflection points within each program 18-24 mon th s Asset Technology Disease area MoA Depletion of pathogenic T cells Preclinical development Clinical development VTX-001 Autoimmune -
Slide 15: Platform can create multiple modalities and is partner validated
ValerioTherapeutics Valerio a n d Etherna ValerioTherapeutics Valerio’s technology pl atf orm c a n create multiple modalities and is partner validated Ta rge ted LNP for e.g. in vivo CAR-T V - Body–Oligonucleotide Conju gate (VOC) Externally va lid ate d pla tform Valerio’s in vivo CAR-T pla tform
Slide 17: A biotech engine for building assets, partnerships and NewCos
ValerioTherapeutics Val ue crea tio n ValerioTherapeutics Valerio Therapeutics is a biotech engine for building assets, partnerships and NewCos Valerio Therapeutics Platform Engine V - Body Discovery Platform mRNA & LNP Platform • sdAb / V-Body functional screening • Linker synthesis & bioconjugatio
Slide 18: Targeted delivery is the latest technology battleground, and the winners drive the deals
ValerioTherapeutics Val ue crea tio n ValerioTherapeutics Targeted delivery is the latest technology battleground, a n d the winners drive the deals $27B+ 8 2 in di sclo se d d el ive ry-dri ve n de al s (20 24– fl ag sh i p p h a rm a acqu isitio ns or l au nche s in 18 mod al it ie s c o nv e rg i

Valerio Therapeutics — Investor Presentation (July 2026) on 6ix

Valerio Therapeutics — Investor Presentation (July 2026)

Slide 1: Valerio Therapeutics: The Precision Delivery Of Oligonucleotides Beyond The Liver

Slide 2: Forward-looking statements

Slide 3: Executive summary: aims to be the next global leader in precision RNA therapeutics

Slide 4: Technology enables LNPs to go from liver-limited to multi-organ tissue targeting

Slide 5: Combines decades of RNA therapeutics development experience with proven leadership

Slide 6: Valerio Technology Platform

Slide 7: Proprietary platform allows significant time saving to generate optimal and customized V-Bodies

Slide 8: The V-Body platform addresses the limitations of sdAbs through unique attributes

Slide 9: Unparalleled in vitro selection process allowing for tailor-made functional binders

Slide 10: Integrated platform allows lead candidate selection in 3 months and development candidate in under 9 months

Slide 11: Valerio Etherna: creating next-generation RNA therapeutics

Slide 12: Combination of Valerio Therapeutics and Etherna will create a global leader in targeted RNA medicines

Slide 13: Combined technologies create a fully integrated platform for targeted RNA therapeutics

Slide 14: Pipeline designed to rapidly reach value inflection points within each program

Slide 15: Platform can create multiple modalities and is partner validated

Slide 16: Valerio's Value Creation

Slide 17: A biotech engine for building assets, partnerships and NewCos

Slide 18: Targeted delivery is the latest technology battleground, and the winners drive the deals